Less than 10% of individuals eligible to benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it releases its first advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for broader and more equitable access to GLP-1 medication.
Per forecasts, over two billion are projected to be living with obesity by 2030 unless action is taken.
"Our new guidelines recognises that obesity is a chronic disease that can be treated with comprehensive and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major obstacles to universal access to the jabs that can aid individuals in losing significant body mass, says the body.
Skinny Jab Supply Crisis
Despite the current best projected case, the manufacturing of such drugs could only cover about 100 million people – fewer than 10% of those who need them, per the health organization.
The recommendation encourages nations and manufacturers to increase access, by approaches such as licensing agreements.
Exclusive production rights on semaglutide – the core component of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Obesity Drugs Function
These medications replicate a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so individuals reduce food intake.
Patients commonly start to lose weight after several weeks of starting on the regular doses.
Evidence suggests people may regain a significant portion after a year of stopping the medication, because their typical food cravings come back.
Being above a healthy weight elevates your risk for experiencing diseases, like diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight affects individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, per the WHO.
